Company news
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A (SZSE:002399) news
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A news releases on 6ix. Latest, May 11, 2026: Resverlogix Announces One-Year Extension of Debenture
View Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A →
Press releases & updates
Resverlogix Announces One-Year Extension of Debenture
May 11, 2026
Shenzhen Hepalink Pharmaceutical : RESIGNATION OF VICE CHAIRMAN AND EXECUTIVE DIRECTOR
May 6, 2021
Shenzhen Hepalink Pharmaceutical : VOLUNTARY ANNOUNCEMENT"HEPTRIS" OBTAINS APPROVAL FROM BRAZILIAN HEALTH REGULATORY AGENCY
April 21, 2021
Shenzhen Hepalink Pharmaceutical : (1) RESIGNATION OF NON-EXECUTIVE DIRECTOR (2) PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR
April 20, 2021
Shenzhen Hepalink Pharmaceutical : VOLUNTARY ANNOUNCEMENT - "INHIXA" OBTAINS APPROVAL FROM NORTH MACEDONIA
April 13, 2021
Shenzhen Hepalink Pharmaceutical : VOLUNTARY ANNOUNCEMENT SETTLEMENT OF THE DISPOSAL OF SHARES OF KYMAB
April 9, 2021
Shenzhen Hepalink Pharmaceutical : "ENOXAPARIN SODIUM INJECTION" OBTAINS APPROVAL FROM FDA
September 21, 2020
Shenzhen Hepalink Pharmaceutical : CHANGE OF JOINT COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES
September 18, 2020
Shenzhen Hepalink Pharmaceutical : CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG
September 11, 2020
Shenzhen Hepalink Pharmaceutical : Hepalink Announces 2020 Interim Results
August 30, 2020
Shenzhen Hepalink Pharmaceutical : Hepalink Announces Exciting Regulatory Developments
June 28, 2020
Shenzhen Hepalink Pharmaceutical : Hepalink Announces the Appointment of Healthcare Senior Executive Mr. Frank Sun as Executive Director and Vice Chairman of the Board
March 5, 2020